Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, David C. Montefiori et al.|The Lancet|2018Cited by 342
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meetingBoris Jülg, Bruce D. Walker, Lynda Dee et al.|The Lancet HIV|2019Cited by 206
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Leyi Lin et al.|The Lancet|2017Cited by 196
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorVincent Dussupt, Nelson L. Michael, Rajeshwer S. Sankhala et al.|Nature Medicine|2020Cited by 88
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R. Baden, Kelly Stanley, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2018Cited by 45